Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_assertion type Assertion NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_head.
- NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_assertion wasGeneratedBy ECO_0000203 NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_provenance.
- NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_assertion wasDerivedFrom befree-20140225 NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_provenance.
- NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_assertion SIO_000772 17091508 NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_provenance.
- NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_assertion evidence source_evidence_literature NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_provenance.
- NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_provenance.